INNOVENT BIO: Third-quarter product revenue exceeded RMB 3.3 billion, a year-on-year increase of approximately 40%

智通財經
2025.10.30 09:32
信達生物公告，2025 年第三季度，公司取得總產品收入超人民幣 33 億元，同比增長約 40%。腫瘤治療領域保持領先地位，產品組合優勢顯著，達伯舒 等主要產品穩健增長，創新產品收入貢獻佔比進一步提升。綜合產品線潛力快速釋放，信爾美 、信必樂 和信必敏 市場準入和渠道營銷工作成效顯著，產品放量加速，收入貢獻顯著擴大。
Source: 智通財經 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.